Objective: To determine whether postmarketing data provide evidence of an association of sibutramine with bruising. Design and patients: During a postmarketing surveillance study of sibutramine in New Zealand by the Intensive Medicines Monitoring Programme (IMMP), a series of reports of bruising was identified. Further case reports were also obtained from the World Health Organisation (WHO) adverse drug reactions database. Outcome measures: All platelet, bleeding and clotting events associated with sibutramine were identified and causality assessments were performed. Results: From the IMMP and WHO databases a total of 16 cases of bruising that improved on withdrawal of sibutramine were identified. Of these, two had a recurrence of bruising on reintroduction of sibutramine. Conclusions: Evidence from postmarketing surveillance suggests that there is a causal association between sibutramine and bruising/ecchymosis. This represents a newly recognized adverse reaction for this medicine.
Introduction
Sibutramine (Meridia s , US, Reductil s , Australia) is a serotonin and noradrenaline reuptake inhibitor licensed worldwide for the management of obesity. Concerns have been raised regarding the safety of this medicine, 1, 2 but recently the FDA decided that the overall risk-benefit profile supported sibutramine remaining available for the treatment of appropriately selected obese patients. 3, 4 Selective serotonin reuptake inhibitors (SSRIs) have been associated with bleeding events, 5, 6 raising the possibility that sibutramine may also have this risk. The US product information for Meridia s states that in premarketing studies bruising/ecchymosis was observed in 0.7% of sibutramine treated patients and in 0.2% of placebo-treated patients. 7 However, literature searches have found no published reports of this potential adverse effect and a causal association has not yet been established.
Methods
The New Zealand Intensive Medicines Monitoring Programme (IMMP) utilizes Prescription Event Monitoring (PEM) methodology to proactively study the safety of monitored medicines in postmarketing use. 8 Cohorts are established using prescription data and reports of adverse events are obtained primarily from follow-up questionnaires sent to patients' doctors.
Monitoring of sibutramine commenced in February 2001 when it was first marketed in New Zealand. The cohort included all patients prescribed sibutramine between 1 February 2001 and 30 November 2002. All clinical events identified for these patients were assessed and coded by clinical assessors using terms from a dictionary based on World Health Organisation Adverse Reaction Terminology (WHOART). 8 Review of all events in the haematology system organ class was conducted to identify all cases of bruising/ ecchymosis. Causality assessment was performed for each case to determine the relationship with the medicine. We identified five reports of bruising/ecchymosis and these are summarized in Table 1 . These cases are not included in the WHO-UMC case reports described below.
WHO-UMC case reports
Search of the WHO-UMC database identified 89 reports in the relevant system organ class, of which 39 were classified as bruising/ecchymosis. Of these 39 reports, 31 had sufficient information for causality assessment. For 11 of these 31 cases there was a positive dechallenge and of these, one patient had a recurrence of ecchymosis on rechallenge. In the remaining 10 cases with a positive dechallenge, either the outcome of rechallenge was unknown or rechallenge was not performed. In two of these cases sibutramine was not the sole suspected drug; aspirin was coadministered in one case and co-trimoxazole in another. The time to onset for these events ranged from 1 to 86 days. Four cases developed bruising within 2 days of starting sibutramine. The case with a positive rechallenge developed ecchymosis 86 days after starting sibutramine. The remaining 20 cases comprised 10 cases in which sibutramine was continued (no dechallenge performed), four cases in which sibutramine was withdrawn but there was no improvement in symptoms, one case where sibutramine had been withdrawn 4 weeks prior to the onset of bruising and five cases in which the result of dechallenge is unknown and thus a relationship could not be determined.
Discussion
During the IMMP's postmarketing safety study of sibutramine, we identified five patients who experienced significant bruising while taking sibutramine. Evidence to support a causal relationship of this adverse event with sibutramine included one case with a positive rechallenge and three cases with a positive dechallenge. Interestingly, there was also a similar time to the onset of the reaction in all of these patients.
Assessment of a further 31 cases from the WHO database provided supporting information. It is likely that the true number of bruising events associated with sibutramine was in fact higher than this as spontaneous reporting systems are well-known to be limited by under-reporting of events.
In total, combining the IMMP and WHO data, 16 cases of bruising that improved on withdrawal of sibutramine were identified. Of these, two had a recurrence of bruising on reintroduction of sibutramine. This evidence suggests that there is a causal association between sibutramine and bruising.
Sibutramine is a potent inhibitor of serotonin reuptake 11 and a possible mechanism by which it may lead to easy bruising involves depletion of platelet serotonin. Platelets release serotonin in the first stages of activation leading to platelet aggregation. Drugs that inhibit serotonin reuptake decrease the amount of serotonin in platelets available for release, and its subsequent activation of 5HT 2A receptors which normally contribute to the aggregatory response.
5,12
Alternative mechanisms might include vascular fragility induced by hyperserotoninaemia 13, 14 or thrombocytopenia.
15
Other SSRI medicines have been associated with a risk of haemorrhagic events.
5,12 A Danish study 16 investigating patients hospitalized for upper GI bleeding provided further evidence for an association between SSRIs and bleeding events, particularly when SSRIs are co-prescribed with NSAIDs. The extent of the risk appears to correlate significantly with the extent of inhibition of serotonin reuptake.
17,18
The incidence of bruising/ecchymosis in premarketing trials of sibutramine was o1%.
7 Analysis of postmarketing data from the IMMP cohort also suggests that the risk of this adverse event is less than one in a hundred. Although it appears that bruising/ecchymosis is not a common adverse reaction to sibutramine, a potential concern is that it may be associated with more serious haemorrhagic events, as has been reported with other serotonin reuptake inhibitors.
16 Two weeks prior to the onset of bruising, this patient developed a subconjunctival haemorrhage. Blood count and clotting screen were normal.
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The product information sheet for Meridia s7 advises caution in patients with a bleeding predisposition or who are on medicines which affect haemostasis or platelet function. The evidence from postmarketing surveillance reviewed in this report suggests that there is a causal association between sibutramine and bruising/ecchymosis and thus supports this prescribing advice. We believe this is the first published report of this newly recognized adverse reaction for sibutramine.
